| Name | Edaravone |
| Description | Edaravone (MCI-186) is a potent new free radical scavenger used for the therapy of patients with acute brain infarction. |
| Cell Research | Cell viability is quantified by MTT assay and trypan blue staining. MTT (5?mg/mL, 20?μL) is added to each well and incubated for 4?h at 37°C after the drug treatments. The medium is removed and the cell pellet is dissolved in DMSO. Then, the optical density (OD) values are measured at 570?nm using an ELISA reader. |
| In vitro | Edaravone significantly improves neurological function in animals. Treatment with edaravone substantially reduces TUNEL-positive apoptotic cells and increases the expression of Bcl-2, while decreasing the immunoreactivity of Bax protein in the peri-infarct area. The research demonstrates that edaravone provides excellent protection against ischemic/reperfusion-induced brain injury through a Bcl-2/Bax protein-dependent anti-apoptotic mechanism. Following a 24-hour infusion of edaravone into murine brain tissue, there is a notable reduction in infarct volume and amelioration of neurological deficits. In the early stages post-reperfusion, edaravone significantly inhibits the accumulation of HNE-modified proteins and 8-OHdG in the penumbral region, reduces the expression of iNOS, diminishes microglial activation, and lowers the formation of nitrotyrosine. Edaravone also markedly attenuates renal function and pathological outcomes in rat kidneys, significantly reducing free radical production in renal tubular epithelial cells as indicated by fluorescence. |
| In vivo | Edaravone optimizes the state of NOS by reducing the detrimental isoforms iNOS and nNOS, while increasing the beneficial eNOS, thus favoring neuroprotection in ischemic stroke. It inhibits oxidation and enhances eNOS expression without boosting production, improving and preserving cerebral blood flow during reperfusion without necessitating peroxynitrite formation. Edaravone exerts its neuroprotective effect by mitigating neuronal damage from cerebral ischemia and inhibiting endothelial injury. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 45 mg/mL (258.32 mM), Sonication is recommended.
|
| Keywords | MMP | MCI186 | MCI 186 | Matrix metalloproteinases | Inhibitor | inhibit | Freeradicalscavengers | Free radical scavengers | Edaravone | Apoptosis |
| Inhibitors Related | Stavudine | 5-Fluorouracil | Cysteamine hydrochloride | Doxycycline (hyclate) | Dextran sulfate sodium salt (MW 4500-5500) | Sodium 4-phenylbutyrate | L-Ascorbic acid | L-Glutamic acid | Doxycycline | Tributyrin | L-Ascorbic acid sodium salt | Alginic acid |
| Related Compound Libraries | Anti-Neurodegenerative Disease Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Anti-Cancer Approved Drug Library | FDA-Approved Drug Library | Cosmetic Ingredient Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Anti-Cancer Drug Library |
United States
